Please login to the form below
Y-mAbs Therapeutics
This page shows the latest Y-mAbs Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Y-mAbs files breakthrough neuroblastoma drug in US
Rare cancer type mostly affects babies and young children. Y-mAbs Therapeutics has filed the first of the two antibody drugs it intends to submit to the FDA, starting with naxitamab ... Y-mAbs reported new results from its main phase 3 naxitamab study at
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval
- AstraZeneca and Innate Pharma to end study on immuno-oncology drug monalizumab
- Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV
- bluebird bio reveals plans to launch two gene therapies
- Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection
- Eli Lilly to make bebtelovimab commercially available to US states from August
- Strategic commitment
- Pfizer set to acquire Global Blood Therapeutics in deal worth $5.4bn
- AstraZeneca and Daiichi Sankyo get FDA approval for breast cancer drug
- NHS England launches hepatitis C screening scheme to reach 2030 elimination goal
- Bayer’s Nubeqa receives FDA approval to treat metastatic prostate cancer
- Valneva and Pfizer initiate phase 3 Lyme disease vaccine study
- Medmeme appoints Dr Joseph Laudano to medical affairs role
- Gilead announces positive Biktarvy data for HIV and hepatitis B
- Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection
- Sarepta to submit application for Duchenne muscular dystrophy gene therapy
- Achieving communication excellence by targeting the right channel at the right time
- Successful product commercialisation: what can we learn from the rare disease setting?
PMHub
Viseven
Viseven is a Global MarTech Services Provider for Pharma and Life Sciences Industries...
Latest intelligence
- Strategic commitment
- ...
- KOL Ambassador Program & Podcast Creation: A Customer Story
- ...
- Animation: Living With
- The journey from the patient's perspective...
